Cargando…

Cell-free DNA from bronchoalveolar lavage fluid (BALF): a new liquid biopsy medium for identifying lung cancer

BACKGROUND: Differentiating malignant lung tumors from benign pulmonary nodules is a great challenge. While the analysis of bronchoalveolar lavage fluid (BALF) is used for diagnosing infections and interstitial lung diseases, there is limited evidence to support its use for lung cancer diagnosis. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Daxiong, Wang, Cangguo, Mu, Chuanyong, Su, Meiqin, Mao, Jingyu, Huang, Jianan, Xu, Jiayue, Shao, Lin, Li, Bing, Li, Haiyan, Li, Bingsi, Zhao, Jun, Jiang, Junhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339831/
https://www.ncbi.nlm.nih.gov/pubmed/34422992
http://dx.doi.org/10.21037/atm-21-2579
_version_ 1783733676601769984
author Zeng, Daxiong
Wang, Cangguo
Mu, Chuanyong
Su, Meiqin
Mao, Jingyu
Huang, Jianan
Xu, Jiayue
Shao, Lin
Li, Bing
Li, Haiyan
Li, Bingsi
Zhao, Jun
Jiang, Junhong
author_facet Zeng, Daxiong
Wang, Cangguo
Mu, Chuanyong
Su, Meiqin
Mao, Jingyu
Huang, Jianan
Xu, Jiayue
Shao, Lin
Li, Bing
Li, Haiyan
Li, Bingsi
Zhao, Jun
Jiang, Junhong
author_sort Zeng, Daxiong
collection PubMed
description BACKGROUND: Differentiating malignant lung tumors from benign pulmonary nodules is a great challenge. While the analysis of bronchoalveolar lavage fluid (BALF) is used for diagnosing infections and interstitial lung diseases, there is limited evidence to support its use for lung cancer diagnosis. This study aimed to interrogate the potential of using BALF cell-free DNA (cfDNA) to discriminate malignant lesions from benign nodules. METHODS: Fifty-three patients with solid pulmonary nodules (≤2 cm) were prospectively enrolled, including 21 confirmed with benign disease and 32 with malignant tumors. Mutations were profiled for 30 tumor tissues and 40 BALFs. Paired BALFs and plasma from 48 patients underwent DNA methylation profiling. A methylome-based classification model was developed for BALF and plasma separately. RESULTS: Among the 30 patients with paired tissues and BALFs, 96.7% and 70% had alterations detected from their tissues (79 alterations) and BALFs (53 alterations), respectively. Using tissues as references, BALFs revealed 14 new alterations and missed 41. BALF mutation displayed a sensitivity of 71%, specificity of 77.8%, and accuracy of 72.5% in detecting lung cancer. BALF methylation achieved an accuracy of 81.3%, with both sensitivity and specificity being 81%. Plasma methylation showed a 66.7% sensitivity, 71.4% specificity, and 68.8% accuracy. BALF methylation also demonstrated 82.4% sensitivity in stage I patients. Parallel bronchoscopy, lavage cytology, and bronchial brushing demonstrated an inferior sensitivity of 23%, 3.1%, and 9.7%, respectively, compared with BALF methylation and mutation (P<0.0001). CONCLUSIONS: BALF cfDNA can serve as a liquid biopsy media for both mutation and methylation profiling, demonstrating better sensitivities in distinguishing small malignant tumors from benign nodules than conventional methods. KEYWORDS: Lung cancer diagnosis; pulmonary nodule; bronchoalveolar lavage fluid (BALF); methylation; genomic mutation
format Online
Article
Text
id pubmed-8339831
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-83398312021-08-20 Cell-free DNA from bronchoalveolar lavage fluid (BALF): a new liquid biopsy medium for identifying lung cancer Zeng, Daxiong Wang, Cangguo Mu, Chuanyong Su, Meiqin Mao, Jingyu Huang, Jianan Xu, Jiayue Shao, Lin Li, Bing Li, Haiyan Li, Bingsi Zhao, Jun Jiang, Junhong Ann Transl Med Original Article BACKGROUND: Differentiating malignant lung tumors from benign pulmonary nodules is a great challenge. While the analysis of bronchoalveolar lavage fluid (BALF) is used for diagnosing infections and interstitial lung diseases, there is limited evidence to support its use for lung cancer diagnosis. This study aimed to interrogate the potential of using BALF cell-free DNA (cfDNA) to discriminate malignant lesions from benign nodules. METHODS: Fifty-three patients with solid pulmonary nodules (≤2 cm) were prospectively enrolled, including 21 confirmed with benign disease and 32 with malignant tumors. Mutations were profiled for 30 tumor tissues and 40 BALFs. Paired BALFs and plasma from 48 patients underwent DNA methylation profiling. A methylome-based classification model was developed for BALF and plasma separately. RESULTS: Among the 30 patients with paired tissues and BALFs, 96.7% and 70% had alterations detected from their tissues (79 alterations) and BALFs (53 alterations), respectively. Using tissues as references, BALFs revealed 14 new alterations and missed 41. BALF mutation displayed a sensitivity of 71%, specificity of 77.8%, and accuracy of 72.5% in detecting lung cancer. BALF methylation achieved an accuracy of 81.3%, with both sensitivity and specificity being 81%. Plasma methylation showed a 66.7% sensitivity, 71.4% specificity, and 68.8% accuracy. BALF methylation also demonstrated 82.4% sensitivity in stage I patients. Parallel bronchoscopy, lavage cytology, and bronchial brushing demonstrated an inferior sensitivity of 23%, 3.1%, and 9.7%, respectively, compared with BALF methylation and mutation (P<0.0001). CONCLUSIONS: BALF cfDNA can serve as a liquid biopsy media for both mutation and methylation profiling, demonstrating better sensitivities in distinguishing small malignant tumors from benign nodules than conventional methods. KEYWORDS: Lung cancer diagnosis; pulmonary nodule; bronchoalveolar lavage fluid (BALF); methylation; genomic mutation AME Publishing Company 2021-07 /pmc/articles/PMC8339831/ /pubmed/34422992 http://dx.doi.org/10.21037/atm-21-2579 Text en 2021 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Zeng, Daxiong
Wang, Cangguo
Mu, Chuanyong
Su, Meiqin
Mao, Jingyu
Huang, Jianan
Xu, Jiayue
Shao, Lin
Li, Bing
Li, Haiyan
Li, Bingsi
Zhao, Jun
Jiang, Junhong
Cell-free DNA from bronchoalveolar lavage fluid (BALF): a new liquid biopsy medium for identifying lung cancer
title Cell-free DNA from bronchoalveolar lavage fluid (BALF): a new liquid biopsy medium for identifying lung cancer
title_full Cell-free DNA from bronchoalveolar lavage fluid (BALF): a new liquid biopsy medium for identifying lung cancer
title_fullStr Cell-free DNA from bronchoalveolar lavage fluid (BALF): a new liquid biopsy medium for identifying lung cancer
title_full_unstemmed Cell-free DNA from bronchoalveolar lavage fluid (BALF): a new liquid biopsy medium for identifying lung cancer
title_short Cell-free DNA from bronchoalveolar lavage fluid (BALF): a new liquid biopsy medium for identifying lung cancer
title_sort cell-free dna from bronchoalveolar lavage fluid (balf): a new liquid biopsy medium for identifying lung cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339831/
https://www.ncbi.nlm.nih.gov/pubmed/34422992
http://dx.doi.org/10.21037/atm-21-2579
work_keys_str_mv AT zengdaxiong cellfreednafrombronchoalveolarlavagefluidbalfanewliquidbiopsymediumforidentifyinglungcancer
AT wangcangguo cellfreednafrombronchoalveolarlavagefluidbalfanewliquidbiopsymediumforidentifyinglungcancer
AT muchuanyong cellfreednafrombronchoalveolarlavagefluidbalfanewliquidbiopsymediumforidentifyinglungcancer
AT sumeiqin cellfreednafrombronchoalveolarlavagefluidbalfanewliquidbiopsymediumforidentifyinglungcancer
AT maojingyu cellfreednafrombronchoalveolarlavagefluidbalfanewliquidbiopsymediumforidentifyinglungcancer
AT huangjianan cellfreednafrombronchoalveolarlavagefluidbalfanewliquidbiopsymediumforidentifyinglungcancer
AT xujiayue cellfreednafrombronchoalveolarlavagefluidbalfanewliquidbiopsymediumforidentifyinglungcancer
AT shaolin cellfreednafrombronchoalveolarlavagefluidbalfanewliquidbiopsymediumforidentifyinglungcancer
AT libing cellfreednafrombronchoalveolarlavagefluidbalfanewliquidbiopsymediumforidentifyinglungcancer
AT lihaiyan cellfreednafrombronchoalveolarlavagefluidbalfanewliquidbiopsymediumforidentifyinglungcancer
AT libingsi cellfreednafrombronchoalveolarlavagefluidbalfanewliquidbiopsymediumforidentifyinglungcancer
AT zhaojun cellfreednafrombronchoalveolarlavagefluidbalfanewliquidbiopsymediumforidentifyinglungcancer
AT jiangjunhong cellfreednafrombronchoalveolarlavagefluidbalfanewliquidbiopsymediumforidentifyinglungcancer